Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Neurogenesis and Regeneration of Nervous Tissue

Neurogenesis and Regeneration of Nervous Tissue

In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

New tools to shape the future of MS and related disorders.

Revue neurologique·2026

Same author

Artificial intelligence in presymptomatic neurological diseases: Bridging normal variation and prodromal signatures.

Revue neurologique·2025

Same author

[Phuc LeHoang: A giant in ophthalmology].

Journal francais d'ophtalmologie·2025

Same author

Cortical blindness as presenting sign of the Heidenhain variant of Creutzfeldt-Jakob disease.

Journal francais d'ophtalmologie·2025

Same author

Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers.

Revue neurologique·2025

Same author

[Changes in global ERG in Birdshot chorioretinopathy and correlation with central macular thickness on OCT].

Journal francais d'ophtalmologie·2025

Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026

Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026

Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026

Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026

Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026

Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 14, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Remyelination and neuroprotection translational trials: Lessons from optic neuritis.

C Louapre¹, Y Beigneux¹, F Maestri²

¹Sorbonne Université, Paris Brain Institute, ICM, Assistance publique-Hôpitaux de Paris, Inserm, CNRS, Hôpital de la Pitié-Salpêtrière, CIC Neurosciences, Paris, France.

Revue Neurologique

|April 12, 2026

Summary

This summary is machine-generated.

Multiple sclerosis treatments improve inflammation but not neurodegeneration. This review examines remyelination and neuroprotection trials in optic neuritis, highlighting challenges for future therapeutic success.

Keywords:

Multiple sclerosis Neuroprotection Optical coherence tomography Remyelination Visual evoked potentials

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Related Experiment Videos

Last Updated: Apr 14, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Area of Science:

Neuroscience
Clinical Neurology
Ophthalmology

Background:

Multiple sclerosis (MS) treatments reduce inflammation but fail to halt progressive neurodegeneration.
Remyelination and neuroprotection are critical therapeutic targets for MS.
The visual pathway, particularly optic neuritis, serves as a valuable model for MS research due to accessible outcome measures.

Purpose of the Study:

To review preclinical and clinical evidence for remyelinating and neuroprotective agents in optic neuritis.
To identify key challenges and methodological lessons from past clinical trials.
To provide insights for improving future translational success in MS therapeutics.

Main Methods:

Systematic review of preclinical studies and clinical trials (Phase 1-3) evaluating remyelinating and neuroprotective agents in optic neuritis.
Analysis of visual evoked potentials (VEPs) and optical coherence tomography (OCT) data.
Synthesis of methodological approaches and outcome measures used in clinical trials.

Main Results:

Numerous clinical trials have investigated remyelinating and neuroprotective strategies in optic neuritis over two decades.
No Phase 3 clinical trial has yet met its primary endpoint for remyelination or neuroprotection in this model.
Identified challenges include optimal intervention timing, patient heterogeneity, assessment variability, and surrogate marker efficacy.

Conclusions:

Despite extensive research, effective remyelinating and neuroprotective therapies for MS via the optic neuritis model remain elusive.
Refining clinical trial design, standardizing outcome measures, and exploring combination therapies are crucial for advancing MS treatment.
Addressing limitations in current trial methodologies is essential for future translational success in combating MS neurodegeneration.